Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

BackgroundThe purpose of this meta-analysis was to compare the safety and efficacy between hypofractionated and conventional fractionation radiotherapy in patients with early-stage breast cancer after breast-conserving surgery.MethodsWe conducted a comprehensive search of PubMed, Embase, Web of Scie...

Full description

Bibliographic Details
Main Authors: Lihu Gu, Wei Dai, Rongrong Fu, Hongfeng Lu, Jingyi Shen, Yetan Shi, Mengting Zhang, Ke Jiang, Feng Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.753209/full
id doaj-8b8d2c6f96634ccf886699854e410409
record_format Article
spelling doaj-8b8d2c6f96634ccf886699854e4104092021-10-01T13:10:35ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-10-011110.3389/fonc.2021.753209753209Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled TrialsLihu Gu0Lihu Gu1Wei Dai2Rongrong Fu3Hongfeng Lu4Jingyi Shen5Yetan Shi6Mengting Zhang7Ke Jiang8Feng Wu9Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, ChinaNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, ChinaThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, ChinaThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, ChinaDepartment of Breast Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, ChinaNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, ChinaNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, ChinaNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, ChinaNingbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, ChinaDepartment of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, ChinaBackgroundThe purpose of this meta-analysis was to compare the safety and efficacy between hypofractionated and conventional fractionation radiotherapy in patients with early-stage breast cancer after breast-conserving surgery.MethodsWe conducted a comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library to identify relevant randomized controlled trials (RCTs) published before February 2021. At the same time, the hazard ratio (HR), risk ratio (RR), and 95% confidence interval (CI) were calculated to evaluate local recurrence (LR), relapse-free survival (RFS), overall survival (OS), adverse events, and cosmetic outcomes.ResultsA total of 14 articles were included in this meta-analysis. Four thousand eight hundred and sixty-nine patients were randomly assigned to the control group to receive conventional radiotherapy (CFRT); 6,072 patients were randomly assigned to the experimental group and treated with hypofractionated radiotherapy (HFRT). The results showed that there was no statistical difference between HFRT and CFRT in LR (HR = 0.99, 95%CI = 0.97–1.02, p = 0.476), RFS (HR = 0.99, 95%CI = 0.97–1.02, p = 0.485), OS (HR = 1.00, 95%CI = 0.97–1.03, p = 0.879), and cosmetic outcomes (RR = 1.03, 95%CI = 0.95–1.12, p = 0.53). In addition, HFRT showed fewer severe adverse reactions such as acute skin toxicity, induration, breast atrophy, and pain.ConclusionOur results suggest that there is no statistical difference between HFRT and CFRT in terms of LR, RFS, OS, and cosmetic outcomes. HFRT reduces the risk of developing toxicity reactions compared to CFRT. HFRT may be a better option for patients with early breast cancer after breast-conserving surgery.https://www.frontiersin.org/articles/10.3389/fonc.2021.753209/fullbreast cancerhypofractionated radiotherapyconventional fractionated radiotherapybreast-conserving surgerymeta-analysis
collection DOAJ
language English
format Article
sources DOAJ
author Lihu Gu
Lihu Gu
Wei Dai
Rongrong Fu
Hongfeng Lu
Jingyi Shen
Yetan Shi
Mengting Zhang
Ke Jiang
Feng Wu
spellingShingle Lihu Gu
Lihu Gu
Wei Dai
Rongrong Fu
Hongfeng Lu
Jingyi Shen
Yetan Shi
Mengting Zhang
Ke Jiang
Feng Wu
Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
Frontiers in Oncology
breast cancer
hypofractionated radiotherapy
conventional fractionated radiotherapy
breast-conserving surgery
meta-analysis
author_facet Lihu Gu
Lihu Gu
Wei Dai
Rongrong Fu
Hongfeng Lu
Jingyi Shen
Yetan Shi
Mengting Zhang
Ke Jiang
Feng Wu
author_sort Lihu Gu
title Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
title_short Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
title_full Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
title_sort comparing hypofractionated with conventional fractionated radiotherapy after breast-conserving surgery for early breast cancer: a meta-analysis of randomized controlled trials
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-10-01
description BackgroundThe purpose of this meta-analysis was to compare the safety and efficacy between hypofractionated and conventional fractionation radiotherapy in patients with early-stage breast cancer after breast-conserving surgery.MethodsWe conducted a comprehensive search of PubMed, Embase, Web of Science, and the Cochrane Library to identify relevant randomized controlled trials (RCTs) published before February 2021. At the same time, the hazard ratio (HR), risk ratio (RR), and 95% confidence interval (CI) were calculated to evaluate local recurrence (LR), relapse-free survival (RFS), overall survival (OS), adverse events, and cosmetic outcomes.ResultsA total of 14 articles were included in this meta-analysis. Four thousand eight hundred and sixty-nine patients were randomly assigned to the control group to receive conventional radiotherapy (CFRT); 6,072 patients were randomly assigned to the experimental group and treated with hypofractionated radiotherapy (HFRT). The results showed that there was no statistical difference between HFRT and CFRT in LR (HR = 0.99, 95%CI = 0.97–1.02, p = 0.476), RFS (HR = 0.99, 95%CI = 0.97–1.02, p = 0.485), OS (HR = 1.00, 95%CI = 0.97–1.03, p = 0.879), and cosmetic outcomes (RR = 1.03, 95%CI = 0.95–1.12, p = 0.53). In addition, HFRT showed fewer severe adverse reactions such as acute skin toxicity, induration, breast atrophy, and pain.ConclusionOur results suggest that there is no statistical difference between HFRT and CFRT in terms of LR, RFS, OS, and cosmetic outcomes. HFRT reduces the risk of developing toxicity reactions compared to CFRT. HFRT may be a better option for patients with early breast cancer after breast-conserving surgery.
topic breast cancer
hypofractionated radiotherapy
conventional fractionated radiotherapy
breast-conserving surgery
meta-analysis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.753209/full
work_keys_str_mv AT lihugu comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT lihugu comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT weidai comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT rongrongfu comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT hongfenglu comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT jingyishen comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT yetanshi comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT mengtingzhang comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT kejiang comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
AT fengwu comparinghypofractionatedwithconventionalfractionatedradiotherapyafterbreastconservingsurgeryforearlybreastcancerametaanalysisofrandomizedcontrolledtrials
_version_ 1716860999441580032